Who are Arm D: FOLFIRI or FOLFOX plus CETUXIMAB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): R-CHOEP 14 with 12x Rituximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arm-d-folfiri-or-folfox-plus-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Arm D: FOLFIRI or FOLFOX plus CETUXIMAB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arm D: FOLFIRI or FOLFOX plus CETUXIMAB (Arm D: FOLFIRI or FOLFOX plus CETUXIMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy combination with monoclonal antibody EGFR (epidermal growth factor receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Arm D: FOLFIRI or FOLFOX plus CETUXIMAB (Arm D: FOLFIRI or FOLFOX plus CETUXIMAB) — Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arm D: FOLFIRI or FOLFOX plus CETUXIMAB TARGET	Arm D: FOLFIRI or FOLFOX plus CETUXIMAB	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	phase 3	Chemotherapy combination with monoclonal antibody	EGFR (epidermal growth factor receptor)
R-CHOEP 14 with 12x Rituximab	R-CHOEP 14 with 12x Rituximab	German High-Grade Non-Hodgkin's Lymphoma Study Group	phase 3	Chemotherapy combination with monoclonal antibody	CD20 (rituximab component); DNA/topoisomerase II (chemotherapy components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with monoclonal antibody class)

German High-Grade Non-Hodgkin's Lymphoma Study Group · 1 drug in this class
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arm D: FOLFIRI or FOLFOX plus CETUXIMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-d-folfiri-or-folfox-plus-cetuximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab